// App-Quantinova.ai

OP0282 (2018) : New systemic sclerosis risk loci identified through a meta-gwas strategy

Researchers

Presenter

  • E. López-Isac

Principal Investigators

  • S. Assassi

  • C.P. Simeón

  • P.E. Carreira

  • I. Castellví

  • N. Ortego-Centeno

  • L. Beretta

  • C. Lunardi

  • A. Gabrielli

  • G. Moroncini

  • N. Hunzelmann

  • T. Witte

  • J.H. Distler

  • A. Franke

  • A.E. Voskuyl

  • J. de Vries-Bouwstra

  • C. Wijmenga

  • R. Hesselstrand

  • A. Nordin

  • A.-M. Hoffmann-Vold

  • A. Herrick

  • J. Worthington

  • C.P. Denton

  • M.A. Brown

  • Y. Allanore

  • T.R. Radstake

  • C. Fonseca

  • M.D. Mayes

  • J. Martín

Medical Centers

  • Instituto de Parasitologia y Biomedicina Lopez- Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain

  • The University of Texas Health Science Center at Houston, Houston, TX

  • Referral Center for Systemic Autoimmune Diseases

  • Università degli Studi di Verona, Verona

  • Universit Politecnica delle Marche Ospedali Riuniti di Ancona, Ancona, Italy

  • Cologne University, Cologne

  • Hannover Medical School, Hannover, Germany

  • University of Erlangen-Nuremberg, Erlangen

  • Christian-Albrechts-University, Kiel, Germany

  • VU University Medical Center, Amsterdam

  • Universitair Medisch Centrum Groningen, Groningen, Netherlands

  • Lund University, Lund, CA

  • Karolinska Institutet, Stockholm, Sweden

  • Oslo University Hospital, Oslo, Norway

  • University of Manchester, Manchester, United Kingdom

  • Royal Free and University College Medical School, London, UK

  • University of Queensland Diamantina Institute, Brisbane, Australia

  • Paris Descartes University, Paris, France

  • University Medical Center Utrecht, Utrecht, Netherlands

  • The University of Texas Health Science Center at Houston, Houston, TX

Locations

  • Spain

  • United States

  • Italy

  • Germany

  • Netherlands

  • Sweden

  • Norway

  • United Kingdom

  • Australia

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A